Skip to search formSkip to main contentSkip to account menu

Selegiline

Known as: L-Deprenyl, (-)-selegiline, Selegiline [Chemical/Ingredient] 
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow… 
National Institutes of Health

Related topics

Related topics

29 relations

Narrower (10)

4-fluorodeprenylDeprenylE-250Eldepryl
Alzheimer's DiseaseAttention deficit hyperactivity disorderDepressive disorderDrug Allergy

Broader (3)

Antiparkinson AgentsMonoamine Oxidase InhibitorsNeuroprotective Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Highly Cited
2006
Highly Cited
2006
Selegiline slows the progression of the symptoms of Parkinson disease
Objective: To study the long-term effects of selegiline in monotherapy and in combination with levodopa in the early phase of… 
Review
2004
Review
2004
Clinical pharmacology of MAO inhibitors: safety and future.
Highly Cited
2000
Highly Cited
2000
MPTP Activates c‐Jun NH2‐Terminal Kinase (JNK) and Its Upstream Regulatory Kinase MKK4 in Nigrostriatal Neurons In Vivo
Abstract: The neuropathology of Parkinson's disease is reflected in experimental animals treated with the selective nigrostriatal… 
Highly Cited
2000
Highly Cited
2000
Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+ homeostasis
Highly Cited
1997
Highly Cited
1997
Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs.
Highly Cited
1995
Highly Cited
1995
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease
Abstract Objective: To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson… 
Highly Cited
1994
Highly Cited
1994
Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments.
Chronic (14 day) but not acute (1 day) treatment of mice with clinically active antidepressants produces a significant… 
Review
1992
Review
1992
The new generation of monoamine oxidase inhibitors.
Irreversible and unspecific inhibitors of MAO were the first modern antidepressants, but after an initial success they fell into… 
Highly Cited
1986
Highly Cited
1986
Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl
Abstract: Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4‐dihydroxyphenyl‐ethylamine (dopamine, DA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)